Skip to content
PeptideWiki.bio

Longevity

NAD+

Also called NAD+, NMN

InjectableEvidence BEvery day
Half-life
0.5hours
Typical vial
100 / 500mg
Research amounts
100–500mg

per administration

Common schedule
Every day
Some human use

It has been used in people, but no trial has settled how much or how often.

Quick start

NAD+ at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.

Typical dose
100–500 mg per administration
How often
Every day
Where
Commonly subcutaneous Sites and rotation
Time to steady level
~3 hours — about five half-lives
Storage
Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details

A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.

Structure note

A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.

Loading the structure…

Work out your draw

These numbers are a starting point — change any of them.

Vial label

Copy this into your label printer.

Published research contexts for NAD+ describe 100500 mg per administration. Descriptive only, not a recommendation.

A cofactor rather than a peptide; its precursors turn over rapidly and a single decay figure does not describe it well.

A cofactor (nicotinamide adenine dinucleotide) and its precursor NMN, catalogued here because people group them with peptides though neither is one. Reported amounts vary widely by route — intravenous infusions, subcutaneous injections and oral precursors are all in circulation — and no single dose-ranging trial fixes a schedule, so the figure above is a nominal placeholder and no schedule table is shown.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.00× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
3hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • NAD+/NMN precursor literatureHuman work covers oral NMN and NR and intravenous NAD+ infusions; amounts vary by route and are not fixed by a dose-ranging trial.

Next steps